Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Primary Myelofibrosis 1Polycythemia Vera 1Mesothelioma, Malignant 1Carcinoma, Non-Small-Cell Lung 1Camurati-Engelmann Syndrome 1Breast Neoplasms 1

Interventions

Pemetrexed 15Cisplatin 13pembrolizumab 6Platinum 41,2-diaminocyclohexaneplatinum II citrate 4cediranib 3Radiotherapy 3Gemcitabine 3Carboplatin 3amatuximab 2Radiotherapy, Intensity-Modulated 2Radiation 2Everolimus 2Drug Therapy 2Cyclophosphamide 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1tremelimumab 1sodium thiosulfate 1sargramostim 1nintedanib 1napabucasin 1methoxyamine 1liposomal doxorubicin 1incomplete Freund's adjuvant 1fresolimumab 1durvalumab 1defactinib 1cixutumumab 1bintrafusp alfa protein, human 1bemcentinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Mesothelioma, Malignant × fresolimumab × Clear all
NCT01112293 2020-04-10

Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma

Abramson Cancer Center at Penn Medicine

Phase 2 Completed
14 enrolled 10 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡